ID   Lu-99
AC   CVCL_3015
SY   LU-99; Lu 99; Lu99; LU99; C-Lu99
DR   BTO; BTO:0006141
DR   CLO; CLO_0050038
DR   ArrayExpress; E-MTAB-2770
DR   BioSample; SAMN03471066
DR   BioSample; SAMN10987825
DR   cancercelllines; CVCL_3015
DR   Cell_Model_Passport; SIDM00546
DR   ChEMBL-Cells; CHEMBL3308600
DR   ChEMBL-Targets; CHEMBL614651
DR   Cosmic; 801578
DR   Cosmic; 808503
DR   Cosmic; 844828
DR   Cosmic; 876174
DR   Cosmic; 946068
DR   Cosmic; 1048224
DR   Cosmic; 1571756
DR   Cosmic; 1656907
DR   Cosmic; 2125270
DR   DepMap; ACH-000444
DR   GEO; GSM887283
DR   GEO; GSM888358
DR   IARC_TP53; 30114
DR   JCRB; JCRB0080
DR   LiGeA; CCLE_430
DR   Progenetix; CVCL_3015
DR   PubChem_Cell_line; CVCL_3015
DR   RCB; RCB1900
DR   TKG; TKG 0495
DR   Wikidata; Q54903211
RX   PubMed=3935627;
RX   PubMed=9290701;
RX   PubMed=11005564;
RX   PubMed=12569360;
RX   PubMed=16105816;
RX   PubMed=22313637;
RX   PubMed=22460905;
RX   PubMed=26589293;
RX   PubMed=30894373;
RX   PubMed=31068700;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: NCI RAS program mutant KRAS cell line panel.
CC   Population: Japanese.
CC   Doubling time: 21.1 hours (Note=Lot 061891), ~25 hours (Note=Lot 10092014) (JCRB=JCRB0080).
CC   HLA typing: A*24:02,24:02; B*52:01,54:01; C*01:02,01:02; DQA1*05:02,05:02; DRB1*03:19,15:02 (PubMed=26589293).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Heterozygous (DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0.25%; Native American=0%; East Asian, North=84.63%; East Asian, South=13.5%; South Asian=0%; European, North=0%; European, South=1.62% (PubMed=30894373).
CC   Derived from site: In situ; Lung; UBERON=UBERON_0002048.
ST   Source(s): JCRB; RCB; TKG
ST   Amelogenin: X
ST   CSF1PO: 10,15
ST   D13S317: 10,11
ST   D16S539: 9
ST   D5S818: 12
ST   D7S820: 11
ST   TH01: 9
ST   TPOX: 11
ST   vWA: 18
DI   NCIt; C4452; Lung giant cell carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   63Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 28
//
RX   PubMed=3935627; DOI=10.20772/cancersci1985.76.10_967;
RA   Yamada T., Hirohashi S., Shimosato Y., Kodama T., Hayashi S.,
RA   Ogura T., Gamou S., Shimizu N.;
RT   "Giant cell carcinomas of the lung producing colony-stimulating factor
RT   in vitro and in vivo.";
RL   Jpn. J. Cancer Res. 76:967-976(1985).
//
RX   PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D;
RA   Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T.,
RA   Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M.,
RA   Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.;
RT   "Screening the p53 status of human cell lines using a yeast functional
RT   assay.";
RL   Mol. Carcinog. 19:243-253(1997).
//
RX   PubMed=11005564; DOI=10.1038/sj.neo.7900094;
RA   Kohno T., Sato T., Takakura S., Takei K., Inoue K., Nishioka M.,
RA   Yokota J.;
RT   "Mutation and expression of the DCC gene in human lung cancer.";
RL   Neoplasia 2:300-305(2000).
//
RX   PubMed=12569360; DOI=10.1038/sj.onc.1206106;
RA   Funakoshi T., Tachibana I., Hoshida Y., Kimura H., Takeda Y.,
RA   Kijima T., Nishino K., Goto H., Yoneda T., Kumagai T., Osaki T.,
RA   Hayashi S., Aozasa K., Kawase I.;
RT   "Expression of tetraspanins in human lung cancer cells: frequent
RT   downregulation of CD9 and its contribution to cell motility in small
RT   cell lung cancer.";
RL   Oncogene 22:674-687(2003).
//
RX   PubMed=16105816; DOI=10.1158/0008-5472.CAN-05-0331;
RA   Nagai Y., Miyazawa H., Huqun X., Tanaka T., Udagawa K., Kato M.,
RA   Fukuyama S., Yokote A., Kobayashi K., Kanazawa M., Hagiwara K.;
RT   "Genetic heterogeneity of the epidermal growth factor receptor in
RT   non-small cell lung cancer cell lines revealed by a rapid and
RT   sensitive detection system, the peptide nucleic acid-locked nucleic
RT   acid PCR clamp.";
RL   Cancer Res. 65:7276-7282(2005).
//
RX   PubMed=22313637; DOI=10.4161/cbt.19238;
RA   Takata M., Chikumi H., Miyake N., Adachi K., Kanamori Y., Yamasaki A.,
RA   Igishi T., Burioka N., Nanba E., Shimizu E.;
RT   "Lack of AKT activation in lung cancer cells with EGFR mutation is a
RT   novel marker of cetuximab sensitivity.";
RL   Cancer Biol. Ther. 13:369-378(2012).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//